Screener
Amneal Pharmaceuticals, Inc. AMRX Hormonal / allergy — Net revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total Affordable Medicines net revenue | 489,913 | 433,425 | 913,150 | 848,133 |
| Specialty | ||||
| Central nervous system | 95,344 | 83,425 | 178,727 | 151,035 |
| Hormonal / allergy | 42,099 | 35,418 | 78,031 | 69,617 |
| Other therapeutic classes | 11,852 | 8,700 | 25,802 | 15,188 |
| Subtotal therapeutic classes | 149,295 | 127,543 | 282,560 | 235,840 |
| License agreement | — | 500 | — | 500 |
| Total Specialty net revenue | 149,295 | 128,043 | 282,560 | 236,340 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported hormonal / allergy — net revenue of $42.1M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue increased by 18.9% year-over-year, from $35.42M to $42.1M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue?
- Over 2 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue has grown at a -44.1% compound annual growth rate (CAGR), from $495.47M to $154.93M.
- What does hormonal / allergy — net revenue mean?
- This metric represents the total gross sales generated by the hormonal and allergy product portfolio after accounting for returns, allowances, and rebates. It serves as a key indicator of the market demand and commercial performance for this specific therapeutic category within the company's broader pharmaceutical offerings. Tracking this revenue stream helps investors assess the segment's contribution to overall top-line growth and its competitive positioning in the specialized pharmaceutical market.
Ask your AI about Amneal Pharmaceuticals, Inc.'s hormonal / allergy — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude